Heather E. Eve

Single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a <scp>UK</scp> phase II study suggest activity and possible gender differences

Heather E. Eve, S. Carey, Sarah J. Richardson et al. · British Journal of Haematology · 2012 · 95 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

Heather E. Eve, David C. Linch, Wendi Qian et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 24 citations

Medicine, Hematology, Oncology +13

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab

Heather E. Eve, John F. Seymour, Simon Rule · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 16 citations

Medicine, Hematology, Oncology +17

Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma

Sarah J. Richardson, Heather E. Eve, J. A. Copplestone et al. · Acta Haematologica · 2009 · 11 citations

Medicine, Oncology, Pharmacology +17